Atricure Inc. Stock
Atricure Inc. Stock
The Atricure Inc. stock is trending slightly upwards today, with an increase of €0.20 (0.600%) compared to yesterday's price.
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Atricure Inc..
As a result the target price of 44 € shows a positive potential of 30.95% compared to the current price of 33.6 € for Atricure Inc..
Pros and Cons of Atricure Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | 0.600% | -2.907% | 21.898% | -46.129% | -1.765% | -46.129% | -51.594% |
| Orthofix Medical Inc. | -15.530% | -1.905% | 22.619% | 11.957% | -20.155% | -39.412% | -66.987% |
| Lantheus Holdings Inc | 0.230% | 0.572% | -10.031% | 39.968% | 53.671% | 27.873% | - |
| Natera Inc | -1.260% | 7.217% | -3.413% | 94.836% | 20.660% | 455.374% | 150.211% |
Comments
AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
